https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55179 Wed 24 Apr 2024 09:34:46 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28081 Wed 11 Apr 2018 13:03:57 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43175 Tue 13 Sep 2022 16:10:37 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52234 Thu 05 Oct 2023 11:39:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:2260 US $382; odds ratio [OR], 3.5; 95% confidence interval [CI], 2.6-4.7) and support for attending international conferences (OR, 5.4; 95% CI, 3.9-7.4). The strongest associations were seen for acting as a paid consultant to industry (OR, 9.0; 95% CI, 3.9-20.4) and for membership on advisory boards (OR, 6.9; 95% CI, 5.1-9.6). There was a strong relationship between research collaboration and accumulation of industry ties. For 1 additional tie the OR was 2.2 (95% CI, 1.2-3.8) and rose to 6.3 (95% CI, 3.5-11.1) with 3 ties and 41.8 (95% CI, 14.5-143.4) with 6 or more ties. Conclusions: Medical specialists who have research relationships with the pharmaceutical industry are much more likely to have multiple additional ties than those who do not have research relationships. Institutional review should discourage clinical researchers from developing multiple ties.]]> Sat 24 Mar 2018 08:27:17 AEDT ]]>